Clinical Trial Update: Safety Study of Subcutaneous Ig NextGen 16% in Patients With Primary Immunodeficiency [Phase 3]

View source ↗

Summary

This update reports the completion of a Phase 3 safety study evaluating subcutaneous immunoglobulin NextGen 16% in patients with primary immunodeficiency.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Immunodeficiency

Drugs mentioned

• NextGen 16% Subcutaneous Immunoglobulin

Snippet

Sponsor: CSL Limited | Conditions: Primary Immune Deficiency | Phase 3 | Status: COMPLETED